Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (799)	5/7/1998 1:35:00 PM
From: Sam Citron	Respond to of 2135

Watson's Letter to Editor of NYT To the Editor: The cancer research of Dr. Judah Folkman and his colleagues is a remarkable step forward (front page, May 3). But we shall not know whether angiostatin and endostatin will cure human cancers until they are tested on humans. The history of cancer research is littered with promised treatments that raised people's hopes, only for them to be dashed when the treatments were put to the test in humans. Your reporter, Gina Kolata, wrote that I predicted Dr. Folkman would "cure cancer in two years." My recollection of the conversation, however, is quite different. What I told Ms. Kolata, at a dinner party six weeks ago, was that endostatin and angio-statin should be in National Cancer Institute clinical trials by the end of this year and that we would know, about one year after that, whether they were effective. This is the most exciting cancer research of my lifetime, and it gives us hope that a world without cancer may yet be attainable. JAMES D. WATSON Pres., Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y., May 4, 1998